Intellia Therapeutics Quarterly Balance Sheet
NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 13.01 -0.46%
Intellia Therapeutics financial position
As of Jun 30, 2026, Intellia Therapeutics reported total assets of $857.2 million, down 4.6% from a year earlier against total liabilities of $129.5 million. Shareholders' equity stood at $727.7 million, or 84.9% of assets. The company held $106.1 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 6.65, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Intellia Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 106.13M | 134.70M | 155.46M | 193.39M | 156.17M | 126.88M | 189.18M | 120.50M | 130.85M | 171.98M | 226.75M | 168.03M |
| Short-Term Investments | 331.63M | 241.29M | 294.42M | 317.65M | 303.48M | 376.87M | 412.33M | 537.62M | 560.22M | 619.32M | 685.48M | 686.76M |
| Receivables | 7.32M | 9.13M | 9.47M | 11.05M | 11.35M | 10.50M | 8.52M | 8.85M | 12.33M | 36.43M | 36.46M | 6.49M |
| Total Current Assets | 527.83M | 466.45M | 527.71M | 581.94M | 495.94M | 551.39M | 639.86M | 710.90M | 757.21M | 884.04M | 998.33M | 893.49M |
| Property, Plant & Equipment | 15.06M | 15.52M | 17.67M | 20.42M | 22.81M | 25.12M | 27.38M | 28.76M | 30.27M | 32.08M | 32.76M | 33.80M |
| Long-Term Investments | 190.59M | 141.26M | 155.25M | 158.81M | 170.85M | 203.35M | 260.21M | 286.57M | 248.81M | 162.09M | 99.86M | 137.75M |
| Total Assets | 857.16M | 758.78M | 842.13M | 925.27M | 898.89M | 986.16M | 1.19B | 1.17B | 1.19B | 1.26B | 1.30B | 1.24B |
| Accounts Payable | 11.71M | 18.80M | 20.25M | 13.26M | 9.80M | 12.36M | 14.59M | 13.14M | 18.82M | 13.69M | 7.45M | 3.55M |
| Total Current Liabilities | 79.39M | 76.44M | 103.88M | 93.73M | 95.50M | 112.59M | 110.85M | 105.68M | 105.09M | 97.91M | 115.21M | 91.95M |
| Total Liabilities | 129.46M | 137.84M | 170.73M | 176.85M | 183.64M | 206.24M | 319.06M | 210.74M | 220.47M | 223.45M | 250.81M | 205.94M |
| Shareholders' Equity | 727.71M | 620.94M | 671.39M | 748.42M | -715.25M | 779.92M | 871.96M | 962.62M | 971.06M | 1.04B | 1.05B | 1.04B |
| Retained Earnings | -2.79B | -2.69B | -2.59B | -2.49B | -2.39B | -2.29B | -2.18B | -2.05B | -1.91B | -1.77B | -1.66B | -1.53B |
| Net Cash (Debt) | 437.76M | 375.99M | 449.88M | 511.04M | 459.65M | 503.75M | 601.51M | 658.11M | 691.07M | 791.29M | 912.22M | 854.79M |
| Shares Outstanding | 140.02M | 120.45M | 116.32M | 115.79M | 105.33M | 103.54M | 102.03M | 101.80M | 98.29M | 96.33M | 93.00M | 89.10M |
This table shows 12 quarterly periods of Intellia Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow NTLA's reporting calendar. What is a balance sheet?